Core Viewpoint - The article discusses the performance and management of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B, highlighting its net asset growth and the background of its fund manager, Wan Minyuan [1][2]. Fund Performance - As of June 30, 2025, the net assets of the Rongtong Health Industry Flexible Allocation Mixed Fund A/B reached 2.074 billion yuan, reflecting a 1.92% increase from the previous period [1]. - The fund's recent performance includes a 15.0% return over the last three months and a 19.86% return over the past year, with a cumulative return of 166.1% since inception [2]. Fund Manager Background - Wan Minyuan, the fund manager, holds a PhD in Biomedical Science from Sichuan University and has extensive experience in the investment sector, having worked at various securities firms and investment management companies since 2011 [1]. Fund Holdings - The top ten stock holdings of the fund include Yixin Tang, Aibo Medical, Sanyou Medical, Jianzhijia, Kaili Medical, Yangguang Nuohuo, Dongfang Biological, Puri Eye Care, Meihua Medical, and Meinian Health, with a combined holding percentage of 57.00% [2]. Company Overview - Rongtong Fund Management Co., Ltd. was established in May 2001 and is based in Shenzhen, focusing on capital market services, with a registered capital of 125 million yuan [2].

Group 1 - The company has not engaged in any cooperation projects with smart glasses-related enterprises as of now [1] - The company will announce any significant business developments in accordance with information disclosure rules in the future [1]

Core Viewpoint - Chengdu Puri Eye Hospital Co., Ltd. has been established with a registered capital of 100 million yuan, focusing on medical services, third-class medical device operations, and eyewear sales excluding contact lenses [1] Company Summary - Chengdu Puri Eye Hospital is fully owned by Puri Eye Care [1] - The company aims to expand its operations in the healthcare sector, particularly in ophthalmology [1] Industry Summary - The establishment of new eye care facilities indicates growth in the healthcare industry, particularly in specialized medical services [1] - The focus on third-class medical devices and eyewear sales reflects a trend towards integrated healthcare solutions [1]

Core Viewpoint - The announcement details the lifting of restrictions on 78,829,585 shares of the company, which represents 52.6869% of the total share capital, allowing these shares to be traded starting from July 7, 2025 [1][2]. Summary by Sections 1. Overview of Shares Before IPO - The company received approval from the China Securities Regulatory Commission for its initial public offering (IPO), issuing 37,404,762 shares on July 5, 2022, increasing the total share capital from 112,214,286 to 149,619,048 shares [1][2]. 2. Changes in Share Capital Post-IPO - Since the IPO, there have been no changes in the number of shares due to profit distribution or capital increases [2]. 3. Commitments from Shareholders for Lifting Restrictions - Shareholders lifting restrictions have made commitments regarding the transfer and management of their shares, including: - The controlling shareholder, Puri Investment, commits not to transfer shares for 36 months post-IPO and to extend the lock-up period if the stock price falls below the issue price [3][4]. - The actual controller, Xu Xuyang, has similar commitments regarding share transfers and management [3][4]. 4. Stock Price Stabilization Measures - The company has established a plan to stabilize its stock price if it falls below the net asset value per share for 20 consecutive trading days within three years post-IPO. Measures include stock buybacks and share purchases by controlling shareholders and management [4][5][6]. 5. Procedures for Stock Buybacks and Share Purchases - The company will initiate buybacks within 10 days of meeting the stabilization criteria, requiring board approval and a shareholder vote [6][7][8]. 6. Commitments to Avoid Conflicts of Interest - The controlling shareholder and actual controller have committed to avoiding any business activities that may compete with the company and to ensure fair dealings in any related transactions [16][17]. 7. Consequences of Non-Compliance with Commitments - If commitments are not fulfilled, the company and its shareholders will face specific penalties, including potential compensation to investors for losses incurred due to non-compliance [18][19]. 8. Final Arrangements for Lifting Share Restrictions - The total number of shares being released from restrictions is 78,829,585, with specific details on the shareholders involved and any shares under pledge [21][22].

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-033 普瑞眼科医院集团股份有限公司 关于首次公开发行前已发行股份解除限售并上市流通 本次上市流通的限售股属于公司首次公开发行前已经发行的股份，限售期 为自公司首次公开发行并上市之日起36个月，股份数量为78,829,585股，占公 司总股本的52.6869%，该部分限售股将于2025年7月7日起上市流通。 二、公司首次公开发行后至今公司股本数量变化情况 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1.本次上市流通的限售股份为普瑞眼科医院集团股份有限公司（以下简称 "公司""发行人"或"普瑞眼科"）首次公开发行前已发行的股份。本次解 除限售的股东户数为6户，股份数量为78,829,585股，占公司总股本的52.6869%， 限售期为自公司首次公开发行股票并上市之日起36个月。 2.本次解除限售股份的上市流通日期为2025年7月7日（星期一）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》 ...

国泰海通证券股份有限公司 关于普瑞眼科医院集团股份有限公司 首次公开发行前已发行股份解除限售并上市流通 的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作 为普瑞眼科医院集团股份有限公司（以下简称"普瑞眼科"或"公司"）首次 公开发行股票并在创业板上市持续督导保荐机构，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》等相关法律、法规和规范性文件的规 定，对普瑞眼科首次公开发行前已发行股份解除限售并上市流通事项进行了核 查，核查的具体情况如下： 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕587号）同意注册，公司首次 公开发行人民币普通股（A股）股票37,404,762股，于2022年7月5日在深圳证券 交易所创业板上市交易。首次公开发行前公司总股本为112,214,286股，首次公 开发行股票完成后公司总股本为149,619, ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-032 普瑞眼科医院集团股份有限公司 关于完成公司名称变更并换发营业执照的公告 名称：普瑞眼科医院集团股份有限公司 统一社会信用代码：91510106785430077J 类型：其他股份有限公司（上市） 住所：成都市金牛区一环路北四段 215 号 法定代表人：徐旭阳 注册资本：壹亿肆仟玖佰陆拾壹万玖仟零肆拾捌元整 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、基本情况 普瑞眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第三届董事会第三十一次会议和 2025 年 5 月 20 日召开的 2024 年度股东 大会审议通过了《关于拟变更公司名称并修订<公司章程>的议案》，同意公司名 称由"成都普瑞眼科医院集团股份有限公司"变更为"普瑞眼科医院集团股份有 限公司"，证券简称、证券代码等其他信息保持不变。具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于拟变 更公司名称并修订<公司章程>的 ...

1 | 第一章 | 总则 4 | | --- | --- | | 第二章 | 经营宗旨和经营范围 5 | | 第三章 | 股份 5 | | 第一节 | 股份发行 5 | | 第二节 | 股份增减和回购 7 | | 第三节 | 股份转让 8 | | 第四章 | 股东和股东会 9 | | 第一节 | 股东 9 | | 第二节 | 控股股东和实际控制人 13 | | 第三节 | 股东会的一般规定 14 | | 第四节 | 股东会的召集 18 | | 第五节 | 股东会的提案与通知 20 | | 第六节 | 股东会的召开 21 | | 第七节 | 股东会的表决和决议 24 | | 第五章 | 董事和董事会 29 | | 第一节 | 董事的一般规定 29 | | 第二节 | 董事会 33 | | 第三节 | 董事会专门委员会 37 | | 第六章 | 高级管理人员 38 | | 第七章 | 财务会计制度、利润分配和审计 40 | | 第一节 | 财务会计制度 40 | | 第二节 | 内部审计 44 | | 第三节 | 会计师事务所的聘任 44 | | 第八章 | 通知和公告 45 | | 第一节 | 通知 45 | ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-031 成都普瑞眼科医院集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份解除质押及累计质押的基本情况 2．股东股份累计质押情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到实际 控制人徐旭阳先生的通知，获悉徐旭阳先生将其所持有的公司部分质押股份办 理了解除质押业务。具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次解除 | 占其所 | 占公司 | 质押起始 | 质押解除 | 质权 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 质押数量 | 持股份 | 总股本 | 日 | 日 | 人 | | | 一致行动人 | （股） | 比例 | 比例 | | | | | | 是 | 3,900,000 | 38.61% | 2.61% | 2023年8月 30日 | 2025年6月 | 云南 | | | | 400,000 | 3 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is gradually recovering, reflected in the performance of listed companies, despite limited overall index growth [1] - The manager emphasizes a balanced approach to investment, focusing on risk-reward ratios and aiming for excess returns relative to the pharmaceutical index over time [1] - The fund manager has a strong track record, with the fund achieving a return of 87.60% since inception, ranking first in its category for various time frames [1] Group 2 - The fund's investment scope includes various segments of the pharmaceutical and healthcare industry, such as chemical pharmaceuticals, traditional Chinese medicine, biological products, and medical services [2] - The top ten holdings of the fund are diversified across high-growth areas like innovative drugs and medical devices, which helps mitigate individual stock volatility while participating in overall industry growth [2] - The holdings are balanced, reducing the risk associated with any single stock and enhancing exposure to the sector's growth potential [2]